氟西汀(百忧解)联合奥氮平治疗帕金森病伴抑郁的疗效观察

Clinical observation of fluoxetine combined with olanzapine in the treatment of patients with Parkinson's disease complicated with depression

目的观察氟西汀联合奥氮平治疗帕金森病伴抑郁患者的临床疗效。方法 120例帕金森病伴抑郁患者随机分为两组,观察组和对照组,各60例,所有患者继续使用原抗帕金森药物,对照组给予氟西汀口服,观察组在对照组用药的基础上口服奥氮平,比较两组的疗效及不良反应。结果观察组的抗抑郁显效率显著高于对照组(86.7%vs68.3%,P<0.05)。两组的HAMD评分和UPDRS评分在治疗后均有不同程度的改善,观察组的效果优于对照组(均有P<0.05)。两组治疗过程中少见不良反应,且发生率差异无统计学意义(P>0.05)。结论氟西汀联合奥氮平治疗帕金森病伴抑郁具有良好的疗效,且不良反应少,值得在临床推广。

Objective To observe the clinical effect of fluoxetine combined with olanzapine in the treatment of patients with Parkinson＇s disease （PD） complicated with depression. Methods One hundred and twenty patients with PD complicated with depression were randomly divided into the study group and the control group, with 60 cases in each group. The control group was given fluoxetine only, and the study group was given fluoxetine and olanzapine. All the patients were treated for 8 weeks. The clinical efficacy was compared between the two groups. Results The total effective rate of the study group was 86.7%, significantly higher than that in the control group （68.3%）, P〈0.05. HAMD score and UPDRS score of the two groups were improved after treatment, and the improvements in the study group was better （all P〈0.05）. Adverse reactions of the two groups were slight during treatment, and there were no sig- nificant different between the two groups （P〉0.05）. Conclusion The clinical effect of fluoxetine combined with olan- zapine is satisfactory and safe for treating PD patients with depression, which is worthy of clinical popularization.